Skip to main content

Anavex

All trials

Alzheimer

Anavex

Leeftijd icoon
60 - 85 years (M / F)
Diagnose icoon
Mild Cognitive Impairment (MCI) due to Alzheimer's, mild-stage Alzheimer's
Duratie onderzoek
52 weeks
Locatie icoon
Amsterdam, Den Bosch and Zwolle

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

A phase IIb / III, double-blind, randomized, placebo-controlled study on the safety and effectiveness of ANAVEX2-73.

The research drug ANAVEX2-73 is a new drug against Alzheimer’s disease.

With this study, the researchers want to learn more about the safety and working mechanisms of the drug. The study drug is administered via capsule (orally).

The research is carried out in the Brain Research Center Amsterdam, Den Bosch, and Zwolle.

This study is commissioned by Anavex.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

Screening – Selection

During a maximum period of four weeks, it will be determined whether you meet the study criteria and whether your general health allows participation in the study. If so, you can participate. Selection takes place at our locations and includes blood tests, physical examinations, memory tests, and questionnaires.

Treatment

In this study, the study drug is compared to a placebo. The chance that you will receive the study drug compared to placebo is 67%. Participants are randomized (randomly assigned) to one of three groups: 30 mg ANAVEX2-73, 50 mg ANAVEX2-73, or placebo. The dosage is slowly built up to 30 mg or 50 mg over a 4-week period. The capsule is taken daily in the morning with breakfast for a duration of 48 weeks. Appointments will be made with you when you should come to our center for check-ups (inquiries about side effects and medication use) and there will be physical and neurological examinations and neuropsychological examinations, in addition to an MRI twice (at the beginning and at the end) and possibly a spinal tap.

A total of 7 visits are made to the research center over a period of 52 weeks.

Who can participate?

  • You have a diagnosis of Mild Cognitive Impairment (MCI) or mild-stage Alzheimer’s disease.
  • You are between 60 and 85 years old.
  • Use of Alzheimer’s medication is allowed, provided it is stable for a period of 90 days prior to screening.
  • You have someone close to you/a caregiver who can accompany you during the visits to the research center and answer questions about your health and functioning.

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials

Filter

All trialsAlzheimer

Alnylam

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALN-APP is for the treatment of participants with MCI or mild dementia due to early onset Alzheimer’s disease, where the disease began before the participant was 65 years old. The study compares the effect of the new drug ALN-APP with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an injection into the fluid surrounding the spinal cord.

audience18+

levelAlzheimer’s or mild dementia due to early onset Alzheimer’s disease

duration152 weeks

locationAmsterdam

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle